Stately Bio has raised a $12 million seed round led by AIX Ventures to advance machine learning techniques that recognize signals from simple images of living cells.

The company said that its test could overcome sensitivity issues with ultrasound and serum alpha-fetoprotein assays that are used to monitor at-risk patients.